A detailed history of Cubist Systematic Strategies, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 1,300 shares of MDGL stock, worth $405,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,300
Holding current value
$405,600
% of portfolio
0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$171.37 - $283.23 $1.25 Million - $2.07 Million
7,291 Added 423.4%
9,013 $2.41 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $207,328 - $408,337
1,722 New
1,722 $398,000
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $1.55 Million - $2.06 Million
6,708 Added 56.37%
18,609 $4.51 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $72,286 - $367,116
1,238 Added 11.61%
11,901 $3.45 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $421,748 - $553,628
6,963 Added 188.19%
10,663 $693,000
Q2 2022

Aug 15, 2022

SELL
$58.04 - $100.2 $127,746 - $220,540
-2,201 Reduced 37.3%
3,700 $265,000
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $611,604 - $1.11 Million
-10,943 Reduced 64.97%
5,901 $579,000
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $1.07 Million - $1.41 Million
14,824 Added 733.86%
16,844 $1.43 Million
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $2.01 Million - $2.69 Million
-25,644 Reduced 92.7%
2,020 $161,000
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $2.69 Million - $3.81 Million
27,664 New
27,664 $2.7 Million
Q1 2021

May 17, 2021

SELL
$108.54 - $125.2 $1.66 Million - $1.91 Million
-15,281 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$110.06 - $133.7 $898,970 - $1.09 Million
8,168 Added 114.83%
15,281 $1.7 Million
Q3 2020

Nov 16, 2020

BUY
$99.78 - $124.21 $395,428 - $492,244
3,963 Added 125.81%
7,113 $845,000
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $45,097 - $94,282
750 Added 31.25%
3,150 $357,000
Q1 2020

May 15, 2020

SELL
$66.76 - $93.49 $740,835 - $1.04 Million
-11,097 Reduced 82.22%
2,400 $160,000
Q4 2019

Feb 14, 2020

BUY
$84.28 - $118.5 $539,729 - $758,874
6,404 Added 90.29%
13,497 $1.23 Million
Q3 2019

Nov 14, 2019

BUY
$84.4 - $106.53 $369,418 - $466,281
4,377 Added 161.16%
7,093 $612,000
Q2 2019

Aug 14, 2019

BUY
$91.13 - $142.5 $111,907 - $174,990
1,228 Added 82.53%
2,716 $285,000
Q1 2019

May 15, 2019

BUY
$103.48 - $143.84 $26,387 - $36,679
255 Added 20.68%
1,488 $186,000
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $71,361 - $162,301
-753 Reduced 37.92%
1,233 $139,000
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $411,697 - $596,415
1,986 New
1,986 $425,000
Q1 2018

May 15, 2018

SELL
$93.35 - $149.04 $123,875 - $197,776
-1,327 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$39.35 - $97.37 $52,217 - $129,209
1,327
1,327 $122,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.34B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.